DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Ithaka Group LLC

Ithaka Group LLC reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,657 shares of the medical device company’s stock after selling 885 shares during the period. DexCom comprises about 2.5% of Ithaka Group LLC’s holdings, making the stock its 16th largest holding. Ithaka Group LLC’s holdings in DexCom were worth $13,453,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Crewe Advisors LLC purchased a new stake in shares of DexCom during the first quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom during the 2nd quarter worth approximately $25,000. DSM Capital Partners LLC purchased a new stake in shares of DexCom in the 4th quarter valued at approximately $28,000. Riverview Trust Co purchased a new stake in shares of DexCom during the 1st quarter worth $32,000. Finally, Sachetta LLC increased its holdings in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on DXCM shares. Piper Sandler reiterated an “overweight” rating and issued a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Oppenheimer cut their target price on DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, July 26th. Royal Bank of Canada cut their price target on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research report on Friday, July 26th. UBS Group cut their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 target price on shares of DexCom in a report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $112.25.

DexCom Stock Up 1.0 %

DXCM stock opened at $69.51 on Monday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a market capitalization of $27.64 billion, a PE ratio of 44.85, a P/E/G ratio of 2.12 and a beta of 1.18. The company’s 50 day simple moving average is $82.36 and its 200-day simple moving average is $111.23.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.34 EPS. Equities analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The disclosure for this sale can be found here. Insiders sold a total of 2,483 shares of company stock valued at $201,708 over the last 90 days. Insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.